

UROLOGY PROTOCOL LIST

HSC #	Site	Stage	Protocol	Status
	PROSTATE			#/goal
10883 (R0415)	Prostate	Low Risk- Primary XRT	Phase III Hypofractionated vs conventional 3D- CRT/IMRT	Open / <15
11015 (R0521)	Prostate	High Risk- Localized	Phase III AS/XRT vs AS/XRT > Taxotere/Pred	Open 1 / <10
10845	Prostate	Neoadjuvant	Role of Soy Isoflavones in Prostate Cancer	Pending / 20
11012 (CALGB 90203)	Prostate	Neoadjuvant	Phase III Docetaxel/AS prior to Rad Prostatectomy vs Immed Rad Prostatectomy	Open / <10
10283 Sanofi	Prostate	Adjuvant- High Risk	Phase III – Eligard/Taxotere vs Eligard vs Deferred Tx	Closed 2 / 13
10701 C11 PET	Prostate	Biochemical Recurrence	Comparison of C11- Acetate PET/CT to ProstaScint	Open 10 / 20
10937 (S0354)	Prostate	2 nd line met/ progression	Phase II CNTO 328	Open 3 / <15
	BLADDER			
10886 (S0353)	Bladder	Superficial Bladder Cancer	Phase II Intravesical Gemzar (prog. after 2 cycles BCG)	Open 0 / <10
11011 (R0524)	Bladder	Muscle Invas. TCC bladder	Phase I/II -Tax/Hercep/XRT vs Taxol/XRT alone	Open / <10
	RENAL			
10750 (E2805)	Renal	Adjuvant- High Risk	Phase III – Sunitinib vs Sorafenib vs Placebo	Open 1 / <100
11005 (rIL-21)	Renal	Metastatic Renal	Phase I/II - Dose escalation rIL-21 + sorafenib	Open 1 /
	ANCILLARY			
9639	Hot flashes	ADT Therapy	Soy vs Placebo	Open 10 / 40

Marilyn Labinski, RN (pager 917-0143)